Alzamend Neuro announced on May 7, 2025, a partnership with Mint Labs Inc. d/b/a QMENTA, a leading medical imaging artificial intelligence company. This collaboration will support Alzamend's five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital.
QMENTA’s cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance and enhancing operational efficiency. Their advanced AI solutions are expected to optimize the imaging workflow across all five clinical studies.
This partnership aims to explore AL001's unique properties and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. The integration of AI-driven imaging technologies is expected to advance safer and more effective treatments for complex neurodegenerative and psychiatric disorders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.